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Abstract
Background: Endometrial carcinoma (EC) is one of the most lethal gynecologic cancers. Patients frequently have
regional or distant metastasis at diagnosis. MicroRNAs are small non-coding RNAs that participate in numerous
biological processes. Recent studies have demonstrated that miR-505 is associated with several types of cancer;
however, the expression and function of miR-505 have not been investigated in EC.
Methods: miR-505 expression in normal endometrial tissue, endometrial carcinomas were quantified by Quantitative
reverse transcription PCR. The endometrial carcinoma cell lines HEC-1B and Ishikawa were each transfected
with miR-505 or scrambled mimics, after which cell phenotype and expression of relevant molecules were
assayed. Dual-luciferase reporter assay and a xenograft mouse model were used to examine miR-505 and its
target gene TGF-α.
Results: RT-PCR results demonstrated that miR-505 was significantly downregulated in human EC tissues compared to
normal endometrial tissues. Besides, miR-505 expression was negatively associated with FIGO stage (stage I-II vs. III-IV),
and lymph node metastasis (negative vs. positive). In vitro, overexpression of miR-505 significantly suppressed EC cell
proliferation, increased apoptosis and reduced migratory and invasive activity. A miR-505 binding site was identified in
the 3′ untranslated region of TGF-α mRNA (TGFA) using miRNA target-detecting software; a dual luciferase reporter
assay confirmed that miR-505 directly targets and regulates TGFA. RT-PCR and Western-blotting results indicated that
overexpressing miR-505 reduced the expression of TGF-α and the TGF-α-regulated proteins MMP2, MMP9, CDK2, while
induced Bax and cleaved-PARP expression in EC cells. In vivo, overexpression of miR-505 reduced the tumorigenicity
and inhibited the growth of xenograft tumors in a mouse model of EC.
Conclusions: Taken together, this study demonstrates that miR-505 acts as tumor suppressor in EC by regulating TGF-α.
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Background
Endometrial carcinoma (EC) is one of the three most
common types of gynecologic cancer and its global inci-
dence has increased in recent years [1]. It is known that
endometrial carcinoma is divided into estrogen dependent
(type I) and non-estrogen dependent (type II) [2, 3]. The
pathogenesis of type I endometrial carcinoma is that
under the long-term effects of estrogen, but without the
antagonistic effects of progesterone, the endometrium
progressively increases in thickness and therefore becomes
more susceptible to becoming cancerous [4, 5]. Generally,
FIGO stage I (2009) endometrial carcinoma is considered
to have a good prognosis with a 5-year survival rate
of up to 96 % [6]. Unfortunately, as multiple factors
affect recurrence, including surgical stage, differenti-
ation and lymph node metastasis, effective therapies
for patients with advanced-stage EC or disease recurrence
are still lacking [7], the 5-year OS rate of the FIGO stages
II–IV was 76.0 % [8]. The identification and further eluci-
dation of the molecular mechanisms responsible for EC
tumorigenesis and progression may have a major impact
on the health of females.
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MicroRNAs are a group of endogenous, small, 18–25
base-long non-coding RNAs that influence multiple
biological processes including proliferation, apoptosis,
senescence, differentiation and development by post-
transcriptionally repressing gene expression or inducing
mRNA degradation via binding to the 3′ untranslated re-
gions (UTR) of specific target genes [9–11]. MicroRNAs
can target approximately 20–30 % of genes. A single
microRNA can target at least 200 genes, and a single gene
can be regulated by many RNAs [12–14]. A large body of
research has demonstrated that dysregulation of micro-
RNAs can promote tumorigenesis and metastasis [15, 16].
Recent studies have demonstrated that microRNAs can
act as either potent oncogenes or tumor suppressor
genes [17].
MiR-505 has been identified to function as a tumor
suppressor in breast cancer [18–20]. Numerous studies
have indicated that miR-505 inhibits cell proliferation by
inducing apoptosis and can promote chemoresistance in
breast cancer [18, 21]. Expression of miR-505 correlates
with established prognostic biomarkers in breast cancer
[22]. Moreover, data from mouse models has indicated
an association between miR-505 and human basal-type
breast cancer [19]. Another study recently provided
evidence that miR-505 could suppress the epithelial-
mesenchymal transition (EMT) and metastasis in naso-
pharyngeal carcinoma [23]. However, little is known about
the biological function and target genes of miR-505 in EC.
Transforming growth factor-α (TGF-α) is a member of
the epidermal growth factor family of mitogens and is
encoded by the TGFA gene. TGF-α binds to the epidermal
growth factor receptor (EGFR) to initiate a series of bio-
logical processes including cell proliferation, differenti-
ation and development [24]. TGF-α makes an important
contribution to cell proliferation and invasion in triple-
negative breast cancer [25], and strongly correlates with
metastasis in advanced prostate cancer [26]. Besides,
TGF-α is also involved in EC tumorigenesis and reported
to promote angiogenesis in endothelial cells [27, 28]. Zhu
et al. reported that miR-152 could potentially controls
migration and invasion by targeting TGF-α in prostate
cancer cell lines [29]; Jin et al. reported that miR-376c
could inhibit cell proliferation and invasion by targeting
TGF-α in osteosarcoma [30]; Qin et al. reported that
miR-124 may regulates TGF-α-induced EMT in human
prostate cancer cells [31]. These studies suggest us that
TGF-a may have potential as a target in inhibiting endo-
metrial cancer tumorigenesis and progression through
down-regulating by relative microRNA. We analyzed the
mRNA sequence of TGF-α and identified binding sites for
miR-505 in TGFA.
Here, we report that miR-505 functions as a tumor
suppressor in EC by targeting and regulating TGFA.
Results
Associations between miR-505 expression and the clinico-
pathological features of EC
Quantitative reverse transcription polymerase chain reac-
tion (qRT-PCR) demonstrated that miR-505 was expressed
at lower levels in human EC than normal endometrial
tissues (Fig. 1a, b, P < 0.05, Additional file 1: Table S1).
Fig. 1 Associations between miR-505 expression and the clinicopathological features of EC. miR-505 mRNA expression was significantly lower in
endometrial adenocarcinoma than in normal endometrial tissues (a-b), and was negatively associated with FIGO stages (c), and Lymph node
metastasis (d). EC = endometrial adenocarcinoma, *P < 0.05
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Besides, miR-505 expression was negatively associated with
FIGO stage (Fig. 1c, stage I/II vs. stage III/IV, P < 0.05), and
lymph node metastasis (Fig. 1d, negative vs. positive, P <
0.05). There were no significant associations between miR-
505 expression and the depth of invasion and pathological
type (endometrial adenocarcinoma vs. other types, P >
0.05, Details could be found in Additional file 1: Table S2).
Overexpression of miR-505 inhibits proliferation, induces
apoptosis and reduces the tumorigenicity of EC cells in
vitro
Ishikawa and HEC-1B cell lines were transfected with
miR-505 mimic or the scrambled mimic. The CCK-8
assay demonstrated that the miR-505 overexpression
(Fig. 2a, P < 0.05) significantly inhibited cell proliferation
in both cell lines compared with the mock or negative
control group (Fig. 2b, P < 0.05). Furthermore, cytometry
flow showed that overexpression of miR-505 induced
significant G1 phase arrest (Fig. 3a, P < 0.05; PI staining)
and high levels of apoptosis (Fig. 3b, P < 0.05, Annexin
V-FITC and PI staining). Additionally, overexpression
of miR-505 significantly reduced the invasion (Fig. 4a,
P < 0.05, Transwell assay) and migratory ability of both
cell lines (Fig. 4b, P < 0.05, wound healing assay). Details
could be found in Additional file 1: Table S3.
miR-505 directly targets TGFA and regulates TGF-α ex-
pression in EC cells
We analyzed the mRNA sequence of TGF-α using the
miRNA target-detecting software and identified binding
sites for miR-505 in TGFA (Fig. 5a). A dual-luciferase
reporter assay indicated that miR-505 can bind to the
3′ UTR of TGFA (Fig. 5b). Furthermore, RT-PCR and
Western blotting demonstrated that overexpression of
miR-505 downregulated the mRNA (Fig. 6a, P < 0.05)
or protein (Fig. 6b, P < 0.05) expression of MMP2, MMP9,
CDK2, and TGF-α, while upregulated Bax and cleaved
PARP expression in both cells.
Overexpression of miR-505 inhibits the growth of EC xe-
nografts in a mouse model
We stably transfected HEC-1B cells with has-miR-505
or negative control vector (Mock) and established a
mouse model of EC. Compared to the mock group,
HEC-1B cells overexpressing miR-505 had a significantly
lower tumor volume (Fig. 7a and b, P < 0.05) and slower
rate of growth (Fig. 7c, P < 0.05). To determine whether
miR-505 affected the expression of TGF-α in vivo, we per-
formed immunohistochemical staining of the excised
xenograft tumors. The tumors formed by the cells overex-
pressing miR-505 had a significantly lower TGF-α expres-
sion compared to the mock group (Fig. 8a and b).
Fig. 2 miR-505 overexpression suppresses endometrial carcinoma cell proliferation in vitro. miR-505 transfection exhibited significantly higher
miR-505 expression (a) and slower growth ability (b) compared with the control and mock cells. Results are representative of three separate
experiments; data are expressed as the mean ± standard deviation, *P < 0.05
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Discussion
This study demonstrates that miR-505 is significantly
downregulated in human EC compared to normal endo-
metrial tissues, and the expression of miR-505 was
significantly associated with the FIGO stage and lymph
node metastasis. Additionally, overexpression of miR-
505 significantly inhibited EC cell proliferation, induced
G1-S arrest and apoptosis, and suppressed EC cell inva-
sion and migration in vitro. Taken together, this data
indicates that downregulation of miR-505 could promote
the development and progression of EC.
The growth factor TGF-α is mainly secreted during
embryogenesis and is frequently overexpressed in malig-
nant tumors, including osteosarcoma, hepatic cancer,
prostate cancer and breast cancer [20, 22, 26, 32, 33].
Recent studies have linked TGF-α overexpression to
the invasive ability of triple-negative breast cancer cells
[34]. Interestingly, overexpression of TGF-α could interact
with mesenchymal-to-epithelial transition (MET) and con-
tribute to cetuximab resistance in patients with colorectal
cancer [35, 36]. High TGF-α expression was prognostic for
poor overall survival in high-risk patients with melanoma
Fig. 3 miR-505 overexpression induces G1 phase arrest and promotes apoptosis of endometrial carcinoma cells. MiR-505 transfection significantly
induced G1 arrest (a) and elevated apoptosis (b) compared with the control and mock cells. Results are representative of three separate experiments;
data are expressed as the mean ± standard deviation, *P < 0.05
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[37]. In this study, target prediction software identified a
miR-505 binding site in the 3′ UTR of TGFA, and dual-
luciferase reporter assays confirmed that TGFA is a direct
target of miR-505. In confirmation of this functional inter-
action, overexpression of miR-505 reduced both TGF-α
mRNA and protein expression in EC cell lines.
TGF-α binds to the epidermal growth factor receptor
(EGFR) to initiate multiple cellular events, including cell
proliferation, and this process has been associated with
tumorigenesis and angiogenesis [38, 39]. We infer that
upregulation of miR-505 may inhibit proliferation, migra-
tion and invasion; promote apoptosis in EC by leading to
Fig. 4 Effects of miR-505 transfection on invasive and metastatic ability of endometrial adenocarcinoma cell lines in vitro. miR-505 overexpression
reduced cell migration (a), and invasion ability (b) compared with the control and mock cells. Results are representative of three separate experiments;
data are expressed as the mean ± standard deviation, *P < 0.05
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decreased expression of TGF-α. MMP2 and MMP9 are
two of the most studied members of the matrix metallo-
proteinase (MMPs) family, and play central roles in cell
invasion and metastasis by cleaving components of the
extracellular matrix (ECM) [27]. In this study, overexpres-
sion of miR-505 downregulated both MMP2 and MMP9
mRNA and protein expression, providing further evidence
that upregulation of miR-505 may inhibit invasion and
metastasis in EC.
During late G1 phase, the CDK2/cyclin E complexes
regulate the G1 to S phase transition and the CDK2/cyclin
A complexes play an important role in S phase progres-
sion [40, 41]. Bcl-2 associated X protein (Bax) is a repre-
sentative member of Bcl-2 family that promotes apoptosis
via the caspase-dependent pathway and is frequently
downregulated in cancer [42]. Poly ADP-ribose polymer-
ase (PARP) participates in DNA repair and can inhibit
apoptosis [43–45]. In this study, overexpression of miR-
505 reduced CDK2 mRNA and protein expression, upreg-
ulated Bax and increased the levels of cleaved PARP.
Therefore, these results indicate that upregulation of miR-
505 promotes apoptosis in EC by upregulating Bax and
PARP and inducing G1-S stage arrest via downregulation
CDK2.
A mouse model of EC was established to further investi-
gate the function of miR-505 in EC in vivo. Overexpres-
sion of miR-505 significantly inhibited tumor xenograft
growth and led to a reduced tumor volume. IHC
staining confirmed that the tumors formed by miR-505-
transfected cells expressed lower levels of TGF-α. These
results provide further confirmation that miR-505 might
act as tumor suppressor in EC by targeting TGFA.
Conclusion
In conclusion, we demonstrate that miR-505 suppresses
cell proliferation, invasion and metastasis in EC by tar-
geting TGFA. This knowledge may provide the basis for
further investigations to identify novel diagnostic and
therapeutic methods for EC.
Methods
Tissue specimen collection
67 Endometrial adenocarcinomas (ECs) and 20 normal
endometrial specimens were collected from patients who
underwent surgical resection at the Gynecology Depart-
ment, First Affiliated Hospital of China Medical University
(Shenyang, Liaoning Province, China) between May 2013
and May 2015. No patients had received any treatment
before surgery. Tumor staging and pathology were based
on the FIGO criteria (2009). The China Medical Univer-
sity ethic committee approved this research project and
informed consent was obtained from each patient. Tissues
were immediately frozen in liquid nitrogen and stored at
−80 °C until analysis.
Cell culture and transfection
The human endometrial cancer cell lines HEC-1B
(poorly differentiated, estrogen receptor-negative endomet-
rial adenocarcinoma) and Ishikawa (highly differentiated,
estrogen receptor-positive endometrial adenocarcinoma)
were obtained from the ATCC (Manassas, VA, USA)
and maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10 % fetal bovine serum and 1 %
penicillin and streptomycin at 37 °C in a humidified
atmosphere containing 5 % CO2. Cells were each
transfected with miR-505 mimic using Lipofectamine
2000 reagent (Invitrogen, Carlsbad, USA) according to the
manufacturer’s protocol. The miR-505 mimic sequence
was GGG AGC CAG GAA GUA UUG AUG U, and the
scrambled mimic (Mock) sequence was ACU ACU GAG
UGA CAG UAG A. The scrambled mimic was also trans-
fected in cells as negative control.
Cell proliferation assay
Cell proliferation was monitored using CCK-8 reagent
(Dojindo, Tokyo, Japan) following the manufacturer’s
protocol. EC cells were transfected with miR-505 mimic
or scrambled mimic, seeded into 96-well plates (2 × 103
cells per well) and incubated until adherent. Cell prolif-
eration was assessed every 24 h (up to 72 h); 10 μL
CCK-8 solution was added to the medium in each well,
Fig. 5 miR-505 directly targets TGFA. The predicted seed region in
the 3′ UTR of TGF-α (a); Luciferase activity is unchanged when using
a scrambled miRNA sequence or miR-505 with the mutant 3′-UTR
of TGF-α. However, when the wild-type 3′-UTR of TGF-α is used, the
promoter activity is significantly reduced by miR-505 (b). Results are
representative of three separate experiments; data are expressed as
the mean ± standard deviation, *P < 0.05
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incubated for 4 h and the absorbance values were
measured at 450 nm using a microplate reader.
Cell cycle analysis
Cells were trypsinized, harvested, washed twice with PBS,
fixed with 70 % ice-cold ethanol in −20 °C overnight,
washed with PBS, and then incubated with RNAase and
stained with PI (BD Biosciences, New Jersey, USA) follow-
ing the manufacturer’s protocol. The PI signal was exam-
ined by a flow cytometry; a total of 10,000 cells were
assessed for each sample.
Apoptosis assay
Apoptosis was quantified using 7AAD and PE-labeled
Annexin V (BD Biosciences) following the manufacturer’s
protocol and flow cytometry. Cells were collected 48 h
after transfection, washed twice with cold PBS, and resus-
pended at 1 × 106 cells/mL and mixed with 100 μL of 1×
buffer and 5 μL Annexin V- PE and 7AAD, incubated for
15 min in the dark, 400 μL 1× buffer was added, and the
cells were subjected to cytometry flow within 1 h.
Wound healing assay
Cells were seeded into 6-well plates, allowed to adhere
and transfected with miR-505 mimic or scrambled mimic,
linear wounds were created in the confluent monolayers
using a pipette tip. Cells were washed three times with
PBS, the medium was changed to FBS-free DMEM, and
photos were captured using a light microscope at 0 h,
24 h and 48 h. The wound healing rate = (Area of original
wound −Area of actual wound at different times)/Area of
original wound × 100 %.
In vitro cell invasion assay
Cells transfected with miR-505 mimic or mock mimic
were collected after 48 h, re-suspended in serum-free
DMEM medium, and 5 × 104 cells in serum-free medium
were seeded into the upper chamber of Transwell inserts
that had been pre-coated with Matrigel (40 μL of 8 mg/mL
Fig. 6 Effects of miR-505 transfection on endometrial adenocarcinoma cell genotype in vitro. miR-505 overexpression reduced TGF-α, CDK2,
MMP2 and MMP9 expression, while increased cleaved PARP and Bax mRNA (a) or protein (b) expression. *P < 0.05
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stock solution; Becton-Dickinson Labware, Bedford, MA,
USA); normal culture medium was placed into the lower
chamber. Cells were allowed to migrate for 48 h at 37 °C,
then the membranes were fixed with methanol and stained
with 0.1 % crystal violent. Cell invasion was measured by
counting the number of cells attached to the lower side of
the membrane in ten high-powered (200×) fields under a
light microscope.
Quantitative RT-PCR
Total RNA was isolated from the treated cells and hu-
man tissues using TRIzol reagent (Takara, Shiga, Japan)
Fig. 8 Overexpression of miR-505 inhibits TGF-α expression in vivo. Immunohistochemical analysis demonstrated a significant reduction of TGF-α
expression in the HSA-miR-505 group (b) compared with the mock group (a) in nude mice tumor tissues
Fig. 7 Overexpression of miR-505 inhibits the growth of tumor xenografts in a mouse model. Tumor xenograft volume in nude mice treated with
miR-505 was smaller than that in mock nude mice (a and b). The growth rate was also slower than that in the mock group (c). *P < 0.05
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according to the manufacturer’s instructions, after which
OD260/280/320 was measured by spectrophotometer
(Unico, Shanghai, China). The value of OD260/280 within
1.8–2.0 means high RNA quality, and the sample concen-
tration = sample dilution factor * (OD260-OD320) * 0.04.
2 μg was reverse-transcribed to complementary DNA
(cDNA) using avian myeloblastosis virus transcriptase and
random primers (Takara). Real-time RT-PCR analysis was
performed in triplicate on the ABI prism 7000 sequence
detection system (Applied Biosystems) using the SYBR
Green PCR Master Mix (Applied Biosystems, Eugene, OR,
USA). The relative expression of target genes was deter-
mined by comparing the threshold cycle (Ct) of the target
genes to the Ct of 18S rRNA (18 s) using the 2-ΔΔCT
method [46]. Hairpin-it™ microRNA and U6 snRNA
Normalization RT-PCR Quantitation (GenePharma) was
used to check mature miR-505 in cells.
Western blotting
Cells and tissues were lysed in ice-cold RIPA lysis buffer
and the concentrations were measured using the protein
assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Protein samples (60 μg) were separated by SDS-PAGE
on 10 % gels and transferred onto Hybond membranes
(Amersham, Munich, Germany). After blocking with 5 %
fat-free milk for 1 h, the membranes were incubated
with primary antibodies against MMP2, MMP9, Cyclin
A1, CDK2, Bax, PARP, TGF-α (1:500, Proteintech, Pro-
teintech Group, USA) and GAPDH (1:2000, Proteintech,
Proteintech Group, USA) overnight in 4 °C, then incu-
bated with anti-mouse, anti-rabbit or anti-goat IgG sec-
ondary antibodies (1:5000; Dako, Carpinteria, CA, USA)
for 1 h. The bands were developed using ECL Plus detec-
tion reagent (Santa Cruz Biotechnology) and visualized on
X-ray film (Fujifilm, Tokyo, Japan) using Image Quant
LAS 4000 (Fujifilm). Band densities were determined and
expressed relative to the internal control GAPDH.
Dual-luciferase reporter assay
Luciferase assays were carried out to confirm the inter-
action between miR-505 and the 3′ untranslated region
(UTR) of TGFA. HEK293T cells were seeded into 24-well
plates, cotransfected with 50 nM miR-505 or scrambled
mimic and 600 ng of dual luciferase vector expressing the
wild-type or mutant 3′-UTR TGF-α sequences. After 24 h,
the luciferase activities were measured using the Dual-
Luciferase Reporter Assay System (Promega, Madison, WI,
USA) according to the manufacturer’s protocol. The ratio
of firefly to renilla luciferase signal was used to normalize
firefly activity for intra-experimental transfection efficiency.
In vivo tumorigenesis model
An in vivo model of EC was established by subcutane-
ously injecting 5-week-old female BALB/c nude mice
with 1 × 107 HEC-1B cells transfected with miR-505 (or
mock transfected) suspended in PBS (10 mice per group).
The weight of the mice and tumor volumes were deter-
mined every 3 days; tumor volume was assessed by meas-
uring the length (L) and width (W) using calipers (tumor
volume, mm3 = 0.5 × L× W2. After 8 weeks, the mice were
euthanized and the tumors were excised, measured and
photographed. All mice were obtained from Shanghai
SLAC Laboratory Animal, Co., Ltd. (Shanghai, China) and
housed in a specific pathogen-free environment. This
experiment was in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Ani-
mals and approved by China Medical University Animal
Care and Use Committee.
Immunohistochemistry
Consecutive tissue sections of the xenograft tumors
were subjected to IHC to detect TGF-α expression. After
deparaffinization, dehydration and boiling to unmask anti-
gens, sections were blocked and incubated with TGF-α
antibodies overnight at 4 °C, then incubated with HRP-
conjugated anti-rabbit antibodies (Dako) for 15 min.
Statistical analysis
Data are presented as mean ± SD and were analyzed
using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).
The unpaired two-tailed Student’s t-test, Mann–Whitney
U-test and Spearman’s correlation test were used to
compare the two groups. All P-values are two-sided;
P < 0.05 represents statistical significance.
Additional file
Additional file 1: Table S1. miR-505 expression in normal endometrial
and endometrial. Table S2. Correlation of miR-505 expression with different
clinicopathological features of endometrial carcinoma. Table S3. Cell
phenomenon studies. (DOCX 24 kb)
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